Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482398 | 0.98 | CYP1A2 (0.44) | CYP1A2TSHRALDH1A1NAAAADH1A | |
| SCHEMBL1482415 | 0.98 | CYP1A2 (0.44) | CYP1A2TSHRALDH1A1NAAAADH1A | |
| SCHEMBL891565 | 0.98 | CYP1A2 (0.44) | CYP1A2TSHRALDH1A1NAAAADH1A | |
| SCHEMBL919373 | 0.95 | — | — | |
| SCHEMBL22444 | 0.93 | CYP1A2 (0.39) | CYP1A2TSHRNAAA | |
| SCHEMBL1524591 | 0.91 | TSHR (0.41) | CYP1A2TSHRNAAAADH1CADH1A | |
| SCHEMBL9205907 | 0.91 | TSHR (0.41) | CYP1A2TSHRNAAAADH1CADH1A | |
| SCHEMBL3026715 | 0.91 | TSHR (0.41) | CYP1A2TSHRNAAAADH1CADH1A | |
| SCHEMBL22042636 | 0.91 | TSHR (0.41) | CYP1A2TSHRNAAAADH1CADH1A | |
| SCHEMBL2407509 | 0.91 | TSHR (0.41) | CYP1A2TSHRNAAAADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | claimed |
| EP-1654225-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| EP-1654225-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | Amgen, Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | AMGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005019240-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-0259752-A2 | Saccharide phosphates, their esters and method for their preparation | BAYER AG (DE) | 1988-03-16 | — | — | EP | claimed |
| US-20240026145-A1 | OPHTHALMIC LENS | MENICON CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4225829-A1 | PROCESS FOR THE MANUFACTURE OF SULFONATED POLYARLYENE(ETHER) SULFONES | BASF SE (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-11705555-B2 | Electrolyte materials for use in electrochemical cells | SION POWER CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4206797-A1 | OPHTHALMIC LENS | Menicon Co., Ltd. (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-116322954-A | Method for producing sulfonated polyarylene (ether) sulfones | 巴斯夫欧洲公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115997158-A | Ophthalmic lens | 株式会社目立康 | 2023-04-21 | — | — | CN | disclosed |
| US-4574122-A | ANTIBODIES, IMMUNOLOGY | BAYER AKTIENGESELLSCHAFT (DE) | 1986-03-04 | — | — | US | disclosed |
| EP-0155625-A2 | Glycolipid-like substances in liposome form | BAYER AG (DE) | 1985-09-25 | — | — | EP | disclosed |
| EP-0149760-A2 | Substituted O-acyl glycosylamides, methods for their preparation and their use | BAYER AG (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0149093-A2 | N-glycosylated ureas, carbamates and thiocarbamates, their preparation method and their use | BAYER AG (DE) | 1985-07-24 | — | — | EP | disclosed |
| EP-0144894-A2 | Therapeutic application of substituted O-acyl-glycosides | BAYER AG (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0143385-A2 | Phosphorylised glycosil amides, ureas, carbamates and thiocarbamates, method for their preparation and their use | BAYER AG (DE) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | MCHR1, MC1R, NPY1R | CYP1A2 394/4885TSHR 19/4885ALDH1A1 1836/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | CYP1A2 193/4885TSHR 3602/4885ALDH1A1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.